The DOI matches its Crossref record; 416 of the 416 references it cites were found in a registry or an index.
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers
Abstract
Background: Updated National Academy of Clinical Biochemistry (NACB) Laboratory Medicine Practice Guidelines for the use of tumor markers in the clinic have been developed. Methods: Published reports relevant to use of tumor markers for 5 cancer sites—testicular, prostate, colorectal, breast, and ovarian—were critically reviewed. Results: For testicular cancer, α-fetoprotein, human chorionic gonadotropin, and lactate dehydrogenase are recommended for diagnosis/case finding, staging, prognosis determination, recurrence detection, and therapy monitoring. α-Fetoprotein is also recommended for differential diagnosis of nonseminomatous and seminomatous germ cell tumors. Prostate-specific antigen (PSA) is not recommended for prostate cancer screening, but may be used for detecting disease recurrence and monitoring therapy. Free PSA measurement data are useful for distinguishing malignant from benign prostatic disease when total PSA is <10 μg/L. In colorectal cancer, carcinoembryonic antigen is recommended (with some caveats) for prognosis determination, postoperative surveillance, and therapy monitoring in advanced disease. Fecal occult blood testing may be used for screening asymptomatic adults 50 years or older. For breast cancer, estrogen and progesterone receptors are mandatory for predicting response to hormone therapy, human epidermal growth factor receptor-2 measurement is mandatory for predicting response to trastuzumab, and urokinase plasminogen activator/plasminogen activator inhibitor 1 may be used for determining prognosis in lymph node–negative patients. CA15-3/BR27–29 or carcinoembryonic antigen may be used for therapy monitoring in advanced disease. CA125 is recommended (with transvaginal ultrasound) for early detection of ovarian cancer in women at high risk for this disease. CA125 is also recommended for differential diagnosis of suspicious pelvic masses in postmenopausal women, as well as for detection of recurrence, monitoring of therapy, and determination of prognosis in women with ovarian cancer. Conclusions: Implementation of these recommendations should encourage optimal use of tumor markers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–400 of 416
Yamauchi, H., Stearns, V., & Hayes, D. F. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2334 · Cited by 291
Self-citationMohsin, S. K., Weiss, H., Havighurst, T., Clark, G. M., Berardo, M., Roanh, L. D., To, T. V., Zho, Q., Love, R. R., & Allred, D. C. (2004) · Modern Pathology · doi:10.1038/modpathol.3800229 · Cited by 290
P53 abnormalities and outcomes in colorectal cancer: a systematic review
Munro, A. J., Lain, S., & Lane, D. P. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602358 · Cited by 289
Wiedswang, G., Borgen, E., Kåresen, R., Kvalheim, G., Nesland, J. M., Qvist, H., Schlichting, E., Sauer, T., Janbu, J., Harbitz, T., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.009 · Cited by 284
Jones, T. D., Ulbright, T. M., Eble, J. N., Baldridge, L. A., & Cheng, L. (2004) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200407000-00014 · Cited by 283
Rustin, G. J. S., Nelstrop, A. E., Tuxen, M. K., & Lambert, H. E. (1996) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a010602 · Cited by 283
(2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1174 · Cited by 276
Prostate-cancer mortality in the USA and UK in 1975–2004: an ecological study
Collin, S. M., Martin, R. M., Metcalfe, C., Gunnell, D., Albertsen, P. C., Neal, D., Hamdy, F., Stephens, P., Lane, J. A., Moore, R., et al. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70104-9 · Cited by 272
Prostate-Specific Antigen Values at the Time of Prostate Cancer Diagnosis in African-American Men
Moul, J. W. (1995) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1995.03530160029029 · Cited by 271
Alpha1-Fetoprotein (AFP) Reference Values in Infants up to 2 Years of Age
Blohm, M. E. G., Vesterling-Hörner, D., Calaminus, G., & Göbel, U. (1998) · Pediatric Hematology and Oncology · doi:10.3109/08880019809167228 · Cited by 268
Edler, D., Glimelius, B. L. G., Hallström, M., Jakobsen, A. K. M., Johnston, P. G., Magnusson, I., Ragnhammar, P., & Blomgren, H. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.07.039 · Cited by 263
Human chorionic gonadotropin. I. Purification and physicochemical properties.
Bahl, O. P. (1969) · PubMed · Cited by 258
CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK)
ALLEN, L. (2003) · Seminars in Oncology · doi:10.1053/j.seminoncol.2003.08.012 · Cited by 257
Tanner, M., Isola, J., Wiklund, T., Erikstein, B., Kellokumpu-Lehtinen, P., Malmström, P., Wilking, N., Nilsson, J., & Bergh, J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.9264 · Cited by 251
Human Tissue Kallikreins: A Family of New Cancer Biomarkers
Diamandis, E. P., & Yousef, G. M. (2002) · Clinical Chemistry · doi:10.1093/clinchem/48.8.1198 · Cited by 247
Self-citationMirza, A. N., Mirza, N. Q., Vlastos, G., & Singletary, S. E. (2002) · Annals of Surgery · doi:10.1097/00000658-200201000-00003 · Cited by 246
ASCO/SSO Review of Current Role of Risk-Reducing Surgery in Common Hereditary Cancer Syndromes
Guillem, J. G., Wood, W. C., Moley, J. F., Berchuck, A., Karlan, B. Y., Mutch, D. G., Gagel, R. F., Weitzel, J., Morrow, M., Weber, B. L., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5260 · Cited by 245
Andriole, G. L., Levin, D. L., Crawford, E. D., Gelmann, E. P., Pinsky, P. F., Chia, D., Kramer, B. S., Reding, D., Church, T. R., Grubb, R. L., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji065 · Cited by 244
Evaluating HER2 amplification and overexpression in breast cancer
Bartlett, J. M. S., Going, J. J., Mallon, E. A., Watters, A. D., Reeves, J. R., Stanton, P., Richmond, J., Donald, B., Ferrier, R., & Cooke, T. G. (2001) · The Journal of Pathology · doi:10.1002/path.971 · Cited by 242
Barnes, D., Harris, W., Smith, P., Millis, R., & Rubens, R. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.563 · Cited by 241
Diamandis, E. P., Scorilas, A., Fracchioli, S., van Gramberen, M., de Bruijn, H., Henrik, A., Soosaipillai, A., Grass, L., Yousef, G. M., Stenman, U.-H., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.022 · Cited by 234
Self-citationColorectal cancer screening: prospects for molecular stool analysis
Davies, R. J., Miller, R., & Coleman, N. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1569 · Cited by 233
Kattan, M. W., Stapleton, A. M. �., Wheeler, T. M., & Scardino, P. T. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19970201)79:3<528::aid-cncr15>3.0.co;2-5 · Cited by 230
Moore, R. G., Brown, A. K., Miller, M. C., Badgwell, D., Lu, Z., Allard, W. J., Granai, C. O., Bast, R. C., & Lu, K. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.04.002 · Cited by 229
Self-citationDuffy, M. J. (2002) · Clinical Chemistry · doi:10.1093/clinchem/48.8.1194 · Cited by 229
Self-citationCirculating tumor cells predict survival in patients with metastatic prostate cancer
Moreno, J. G., Miller, M. C., Gross, S., Allard, W. J., Gomella, L. G., & Terstappen, L. W. M. M. (2005) · Urology · doi:10.1016/j.urology.2004.11.006 · Cited by 223
Scholler, N., & Urban, N. (2007) · Biomarkers in Medicine · doi:10.2217/17520363.1.4.513 · Cited by 220
CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers.
Carpelan-Holmström, M. A., Louhimo, J. M., Stenman, U., Alfthan, H. V., & Haglund, C. (2002) · PubMed · Cited by 216
Self-citationSerum CEA and CA 15-3 as prognostic factors in primary breast cancer
Ebeling, F. G., Stieber, P., Untch, M., Nagel, D., Konecny, G. E., Schmitt, U. M., Fateh-Moghadam, A., & Seidel, D. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600248 · Cited by 215
Screening for Prostate Cancer: Recommendation and Rationale
U.S. Preventive Services Task Force* (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-11-200212030-00013 · Cited by 213
Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810 patients
Foekens, J. A., Look, M. P., Vries, J. B.-D., Gelder, M. E. M.-V., Putten, W. L. J. V., & Klijn, J. G. M. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690048 · Cited by 209
Curing metastatic cancer: lessons from testicular germ-cell tumours
Masters, J. R. W., & Köberle, B. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1120 · Cited by 208
Cancer Prevalence and Survivorship Issues: Analyses of the 1992 National Health Interview Survey
Hewitt, M., Breen, N., & Devesa, S. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.17.1480 · Cited by 207
Follow-up of patients with colorectal cancer
Kievit, J. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00061-8 · Cited by 206
Elsaleh, H., Powell, B. L., McCaul, K. A., Grieu, F., Grant, R., Joseph, D., & Iacopetta, B. J. (2001) · PubMed · Cited by 204
Practice Guidelines for Tumor Marker Use in the Clinic
Sturgeon, C. (2002) · Clinical Chemistry · doi:10.1093/clinchem/48.8.1151 · Cited by 202
Self-citationPrognostic significance of interleukin 6 serum levels in patients with ovarian cancer
Scambia, G., Testa, U., Benedetti Panici, P., Foti, E., Martucci, R., Gadducci, A., Perillo, A., Facchini, V, Peschle, C., & Mancuso, S. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.71 · Cited by 198
Tumor Markers : Physiology, Pathobiology, Technology, and Clinical Applications
Fritsche, H. A., Diamandis, E. P., & Lilja, H. G. (2002) · Cited by 197
Self-citationBirner, P., Oberhuber, G., Stani, J., Reithofer, C., Samonigg, H., Hausmaninger, H., Kubista, E., Kwasny, W., Kandioler-Eckersberger, D., Gnant, M., et al. (2001) · PubMed · Cited by 197
BRCA1 and BRCA2 germline mutation analysis in the Indonesian population
Purnomosari, D., Pals, G., Wahyono, A., Aryandono, T., Manuaba, T. W., Haryono, S. J., & van Diest, P. J. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9493-4 · Cited by 197
Advanced colorectal cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
Van Cutsem, E., & Oliveira, J. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp130 · Cited by 197
HLA-G is a potential tumor marker in malignant ascites.
Singer, G., Rebmann, V., Chen, Y., Liu, H. T., Ali, S. Z., REINSBERG, J., McMaster, M., Pfeiffer, K. A., Chan, D. W., Wardelmann, E., et al. (2003) · PubMed · Cited by 194
Self-citationMechanisms for Lysophosphatidic Acid-induced Cytokine Production in Ovarian Cancer Cells
Fang, X., Yu, S., Bast, R. C., Liu, S., Xu, H.-J., Hu, S.-X., LaPushin, R., Claret, F. X., Aggarwal, B. B., Lu, Y., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m306662200 · Cited by 192
Self-citationFollow-up of colorectal cancer: A meta-analysis
Rosen, M., Chan, L., Beart, R. W., Vukasin, P., & Anthone, G. (1998) · Diseases of the Colon & Rectum · doi:10.1007/bf02239433 · Cited by 192
Harbeck, N., Kates, R. E., Look, M. P., Gelder, M. E. M., Klijn, J. G. M., Krüger, A., Kiechle, M. B., Jänicke, F., Schmitt, M., & Foekens, J. A. (2002) · PubMed · Cited by 191
Self-citationImmunohistochemical detection of steroid receptors in breast cancer: a working protocol: Table 1
Leake, R., Barnes, D., Pinder, S., Ellis, I., Anderson, L., Anderson, T., Adamson, R., Rhodes, T., Miller, K., & Walker, R. (2000) · Journal of Clinical Pathology · doi:10.1136/jcp.53.8.634 · Cited by 189
Popat, S., & Houlston, R. S. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.04.039 · Cited by 187
The Prognostic Significance of Micrometastases in Breast Cancer: A SEER Population-Based Analysis
Chen, S. L., Hoehne, F. M., & Giuliano, A. E. (2007) · Annals of Surgical Oncology · doi:10.1245/s10434-007-9513-6 · Cited by 185
Placental alkaline phosphatase as a tumor marker for seminoma.
Lange, P. H., Millán, J. L., Stigbrand, T. I., Vessella, R. L., Ruoslahti, E., & Fishman, W. H. (1982) · PubMed · Cited by 183
Tumour marker measurements in the diagnosis and monitoring of breast cancer
Cheung, K. L., Graves, C. R. L., & Robertson, J. F. R. (2000) · Cancer Treatment Reviews · doi:10.1053/ctrv.1999.0151 · Cited by 183
uPM3, a new molecular urine test for the detection of prostate cancer
Fradet, Y., Saad, F., Aprikian, A., Dessureault, J., Elhilali, M., Trudel, C., Mâsse, B., Piché, L., & Chypre, C. (2004) · Urology · doi:10.1016/j.urology.2004.03.052 · Cited by 182
MEYTS, E. R., & SKAKKEBKK, N. E. (1994) · International Journal of Andrology · doi:10.1111/j.1365-2605.1994.tb01225.x · Cited by 181
The syndrome of 5-fluorouracil cardiotoxicity. An elusive cardiopathy
Robben, N. C., Pippas, A. W., & Moore, J. O. (1993) · Cancer · doi:10.1002/1097-0142(19930115)71:2<430::aid-cncr2820710225>3.0.co;2-s · Cited by 179
Hendriks, Y. M. C., de Jong, A. E., Morreau, H., Tops, C. M. J., Vasen, H. F., Wijnen, J. T., Breuning, M. H., & Brocker-Vriends, A. H. J. T. (2006) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.56.4.213 · Cited by 178
Facts and Controversies in Systemic Treatment of Metastatic Breast Cancer
Bernard-Marty, C., Cardoso, F., & Piccart, M. J. (2004) · The Oncologist · doi:10.1634/theoncologist.9-6-617 · Cited by 177
Paik, S. (2007) · The Oncologist · doi:10.1634/theoncologist.12-6-631 · Cited by 177
Human kallikrein 6 (zyme/protease M/neurosin): a new serum biomarker of ovarian carcinoma
Diamandis, E. P., Yousef, G. M., Soosaipillai, A. R., & Bunting, P. (2000) · Clinical Biochemistry · doi:10.1016/s0009-9120(00)00182-x · Cited by 176
Self-citationOutcome of Surgery for Clinical Unilateral T3a Prostate Cancer: A Single-Institution Experience
Hsu, C.-Y., Joniau, S., Oyen, R., Roskams, T., & Van Poppel, H. (2007) · European Urology · doi:10.1016/j.eururo.2006.05.024 · Cited by 176
Predictive Markers in Breast and Other Cancers: A Review
Duffy, M. J. (2005) · Clinical Chemistry · doi:10.1373/clinchem.2004.046227 · Cited by 174
Self-citationAmerican Cancer Society Guidelines for the Early Detection of Cancer, 2005
Smith, R. A., Cokkinides, V., & Eyre, H. J. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.1.31 · Cited by 174
Plante, M., Rubin, S. C., Wong, G. Y., Federici, M. G., Finstad, C. L., & Gastl, G. A. (1994) · Cancer · doi:10.1002/1097-0142(19940401)73:7<1882::aid-cncr2820730718>3.0.co;2-r · Cited by 173
de Koning, H. J., Liem, M. K., Baan, C. A., Boer, R., Schröder, F. H., & Alexander on behalf of ERSPC, F. E. (2002) · International Journal of Cancer · doi:10.1002/ijc.10188 · Cited by 170
Overdiagnosis and overtreatment of early detected prostate cancer
Bangma, C. H., Roemeling, S., & Schröder, F. H. (2007) · World Journal of Urology · doi:10.1007/s00345-007-0145-z · Cited by 169
The search for the retinoblastoma cell of origin
Dyer, M. A., & Bremmer, R. (2005) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2005.05.013 · Cited by 168
Sturgeon, C. M., Hoffman, B. R., Chan, D. W., Ch'ng, S.-L., Hammond, E., Hayes, D. F., Liotta, L. A., Petricoin, E. F., Schmitt, M., Semmes, O. J., et al. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2007.094144 · Cited by 166
Self-citationPredictors of Occult Metastasis in Clinical Stage I Nonseminoma: A Systematic Review
Vergouwe, Y., Steyerberg, E. W., Eijkemans, M. J. C., Albers, P., & Habbema, J. D. F. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.094 · Cited by 165
Santillan, A., Garg, R., ZAHURAK, M. L., Gardner, G. J., Giuntoli, R. L., Armstrong, D. K., & Bristow, R. E. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.2582 · Cited by 163
Clinical Uses of Tumor Markers: A Critical Review
Duffy, M. J. (2001) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/20014091084218 · Cited by 161
Self-citationThe clinical evaluation of HER‐2 status: which test to use?
Bartlett, J. M. S., Mallon, E., & Cooke, T. (2003) · The Journal of Pathology · doi:10.1002/path.1354 · Cited by 161
Tumor markers in the management of patients with ovarian cancer
Tuxen, M. K., Sölétormos, G., & Dombernowsky, P. (1995) · Cancer Treatment Reviews · doi:10.1016/0305-7372(95)90002-0 · Cited by 160
Morris, A. D., Morris, R. D., Wilson, J. F., White, J., Steinberg, S., Okunieff, P. G., Arriagada, R., Lê, M. G., Blichert-Toft, M., & van Dongen, J. A. (1997) · PubMed · Cited by 160
Golfinopoulos, V., Salanti, G., Pavlidis, N., & Ioannidis, J. P. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70281-4 · Cited by 159
Bead-Based ELISA for Validation of Ovarian Cancer Early Detection Markers
Scholler, N., Crawford, M., Sato, A., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2007 · Cited by 156
Cheng, L., Thomas, A. B., Roth, L. M., Zheng, W., Michael, H. T., & Karim, F. W. A. (2004) · The American Journal of Surgical Pathology · doi:10.1097/01.pas.0000135528.03942.1f · Cited by 155
Role of gain of 12p in germ cell tumour development
Looijenga, L. H. J., Zafarana, G., Grygalewicz, B., Summersgill, B. M., Dêbiec‐Rychter, M., Veltman, J. A., Schoenmakers, E., Rodriguez, S., Jafer, O., Clark, J., et al. (2003) · Apmis · doi:10.1034/j.1600-0463.2003.11101201.x · Cited by 155
Self-citationPollack, A. S., DeSilvio, M., Khor, L. Y., Li, R., Al‐Saleem, T., Hammond, M. E., Venkatesan, V., Lawton, C. A., Roach, M., Shipley, W. U., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.150 · Cited by 155
Esteva, F. J., Cheli, C. D., Fritsche, H. A., Fornier, M. N., Slamon, D. J., Thiel, R. P., Lüftner, D., & Ghani, F. (2005) · Breast Cancer Research · doi:10.1186/bcr1020 · Cited by 154
Self-citationStephan, C., Klaas, M., Müller, C., Schnorr, D., Loening, S. A., & Jung, K. (2006) · Clinical Chemistry · doi:10.1373/clinchem.2005.059170 · Cited by 154
Self-citationLuo, L., Katsaros, D., Scorilas, A., Fracchioli, S., Bellino, R., van Gramberen, M., de Bruijn, H., Alfthan, H., Stenman, U., Massobrio, M., et al. (2003) · PubMed · Cited by 153
Self-citationLysophosphatidic acid induces urokinase secretion by ovarian cancer cells.
Pustilnik, T. B., Estrella, V. C., Wiener, J. R., Mao, M., Eder, A. M., Watt, M. A. V., Bast, R. C., & Mills, G. B. (1999) · PubMed · Cited by 153
Self-citationEpithelial ovarian cancer: prevention, diagnosis, and treatment
Partridge, E. E., & Barnes, M. N. (1999) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.49.5.297 · Cited by 151
Preoperative CA 125 Levels: An Independent Prognostic Factor for Epithelial Ovarian Cancer
Cooper, B. C., Sood, A., Davis, C. S., Ritchie, J., Sorosky, J., Anderson, B., & Buller, R. (2002) · Obstetrics and Gynecology · doi:10.1016/s0029-7844(02)02057-4 · Cited by 151
DNA-based detection of prostate cancer in urine after prostatic massage
Goessl, C. D., Müller, M., Heicappell, R., et al. (2001) · Urology · doi:10.1016/s0090-4295(01)01268-7 · Cited by 150
Cells lacking CIP1/WAF1 genes exhibit preferential sensitivity to cisplatin and nitrogen mustard
Fan, S., Chang, J. K., Smith, M. L., Duba, D. E., Fornace, A. J., & O'Connor, P. M. (1997) · Oncogene · doi:10.1038/sj.onc.1201052 · Cited by 150
Song, K. S., Fendrick, A. M., & Ladabaum, U. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.02.016 · Cited by 149
Characterization of Active Mitogen-Activated Protein Kinase in Ovarian Serous Carcinomas
Hsu, C., Bristow, R. E., Cha, M. S., Wang, B. G., Ho, C., Kurman, R. J., Wang, T., & Shih, I. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0893 · Cited by 148
Self-citationSölétormos, G., Semjonow, A., Sibley, P. E. C., Lamerz, R., Petersen, P. H., Albrecht, W., Bialk, P., Gion, M., Junker, F., Schmid, H.-P., et al. (2005) · Clinical Chemistry · doi:10.1373/clinchem.2004.046086 · Cited by 146
Self-citationA Novel Approach Toward Development of a Rapid Blood Test for Breast Cancer
Vlahou, A., Laronga, C., Wilson, L., Gregory, B. W., Fournier, K. F., McGaughey, D. S., Perry, R. R., Wright, G. L., & Semmes, O. J. (2003) · Clinical Breast Cancer · doi:10.1016/s1526-8209(11)70627-9 · Cited by 146
Rubin, M. A., Zerkowski, M. P., Camp, R. L., Kuefer, R., Hofer, M. D., Chinnaiyan, A. M., & Rimm, D. L. (2004) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63171-9 · Cited by 145
Early Detection of Ovarian Cancer: Promise and Reality
Bast, R. C., Urban, N. D., Shridhar, V., Smith, D., Zhang, Z., Skates, S. J., Lu, K. H., Liu, J., Fishman, D. A., & Mills, G. B. (2002) · Cancer treatment and research · doi:10.1007/978-1-4757-3587-1_3 · Cited by 143
Self-citationHuhtala, M., Pesonen, K., Kalkkinen, N., & Stenman, U. (1982) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)33505-1 · Cited by 143
Self-citationStenman, U., Alfthan, H. V., RANTA, T., VARTIAINEN, E., Jalkanen, J. T., & Seppälä, M. T. (1987) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-64-4-730 · Cited by 142
Self-citationEstablishing a germ cell origin for metastatic tumors using OCT4 immunohistochemistry
Cheng, L. (2004) · Cancer · doi:10.1002/cncr.20566 · Cited by 140
Woodrum, D. L., French, C., & Shamel, L. (1996) · Urology · doi:10.1016/s0090-4295(96)00607-3 · Cited by 139
Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma
Shih, I., Sheu, J. J., Santillan, A., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504195102 · Cited by 138
Self-citation(2001) · Gastroenterology · doi:10.1053/gast.2001.25580 · Cited by 137
Overexpression of HER-2 in ovarian carcinomas.
Hellström, I., Goodman, G. E., Pullman, J., Yang, Y., & Hellström, K. E. (2001) · PubMed · Cited by 136
Alpha‐methylacyl‐CoA racemase: a multi‐institutional study of a new prostate cancer marker
Jiang, Z., Wu, C., Woda, B. A., Iczkowski, K. A., Chu, P. G., Tretiakova, M., Young, R. H., Weiss, L. M., Blute, R., Brendler, C. B., et al. (2004) · Histopathology · doi:10.1111/j.1365-2559.2004.01930.x · Cited by 134
Pertschuk, L. P., Feldman, J. G., Kim, Y.-D., Braithwaite, L., Schneider, F., Braverman, A. S., & Axiotis, C. A. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960615)77:12<2514::aid-cncr14>3.0.co;2-v · Cited by 133
Prognostic and predictive value of p53 and p21 in breast cancer
Elledge, R. M., & Allred, D. C. (1998) · Breast Cancer Research and Treatment · doi:10.1023/a:1006163101948 · Cited by 132
Nakayama, K., Nakayama, N., Davidson, B., Sheu, J. J., Jinawath, N., Santillan, A., Salani, R., Bristow, R. E., Morin, P. J., Kurman, R. J., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604083103 · Cited by 131
Self-citationMueller, T., Voigt, W., Simon, H., Fruehauf, A., Bulankin, A., Grothey, A. A., & Schmoll, H. (2003) · PubMed · Cited by 131
Mitogen-Activated Protein Kinase
Adam, L. P. (1996) · Elsevier eBooks · doi:10.1016/b978-012078160-7/50016-0 · Cited by 131
Liu, A. X., Testa, J. R., Hamilton, T. C., Jove, R., Nicosia, S. V., & Cheng, J. Q. (1998) · PubMed · Cited by 130
CA 19-9 as a Marker for Gastrointestinal Cancers: A Review
Duffy, M. J. (1998) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/000456329803500304 · Cited by 126
Self-citationFactors influencing serum CA125II levels in healthy postmenopausal women.
Pauler, D. K., Menon, U., McIntosh, M. W., Symecko, H., Skates, S. J., & Jacobs, I. J. (2001) · PubMed · Cited by 124
XIST unmethylated DNA fragments in male-derived plasma as a tumour marker for testicular cancer
Kawakami, T., Okamoto, K., Ogawa, O., & Okada, Y. (2004) · The Lancet · doi:10.1016/s0140-6736(03)15170-7 · Cited by 124
Yang, J. L., Seetoo, D., Wang, Y., Ranson, M., Berney, C. R., Ham, J. M., Russell, P. J., & Crowe, P. J. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20000920)89:5<431::aid-ijc6>3.0.co;2-v · Cited by 124
The measurement and therapeutic implications of circulating tumour cells in breast cancer
Smerage, J. B., & Hayes, D. F. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602871 · Cited by 124
Self-citationWho Should Be Sent for Genetic Testing in Hereditary Colorectal Cancer Syndromes?
Lynch, H. T., Boland, C. R., Rodríguez-Bigas, M. A., Amos, C. I., Lynch, J. F., & Lynch, P. M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.3119 · Cited by 124
Ntais, C., Polycarpou, A., & Ioannidis, J. P. A. (2005) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.176.14.1 · Cited by 123
A critical role for p27 kip1 gene dosage in a mouse model of prostate carcinogenesis
Gao, H., Ouyang, X., Banach-Petrosky, W. A., Borowsky, A. D., Lin, Y., Kim, M., Lee, H., Shih, W. J., Cardiff, R. D., Shen, M. M., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407693101 · Cited by 123
van Echten, J., Oosterhuis, J. W., Looijenga, L. H. J., van de Pol, M., Wiersema, J., Meerman, G. J. T., Koops, H. S., Sleijfer, D. T., & de Jong, B. M. (1995) · Genes Chromosomes and Cancer · doi:10.1002/gcc.2870140208 · Cited by 123
Self-citationEstrogen Receptors: Role in Breast Cancer
Duffy, M. J. (2006) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408360600739218 · Cited by 122
Self-citationHan, K., Seligson, D. B., Liu, X., Horvath, S., Shintaku, P. I., THOMAS, G. V., SAID, J. W., & Reiter, R. E. (2004) · The Journal of Urology · doi:10.1097/01.ju.0000109982.60619.93 · Cited by 122
Harbeck, N., Kates, R. E., & Schmitt, M. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.4.1000 · Cited by 121
Self-citationFerrandina, G., Scambia, G., Bardelli, F., Panici, P. B., Mancuso, S., & Messori, A. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.442 · Cited by 120
Bridgewater, J. A., Nelstrop, A. E., Rustin, G. J. S., Gore, M. E., McGuire, W. P., & Hoskins, W. J. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.2.501 · Cited by 119
Stool screening for colorectal cancer: evolution from occult blood to molecular markers
Ahlquist, D. A., & Shuber, A. P. (2002) · Clinica Chimica Acta · doi:10.1016/s0009-8981(01)00712-4 · Cited by 117
Low Microsatellite Instability Is Associated With Poor Prognosis in Stage C Colon Cancer
Kohonen‐Corish, M. R. J., Daniel, J. J., Chan, C., Lin, B. P. C., Kwun, S. Y., Dent, O. F., Dhillon, V. S., Trent, R. J., Chapuis, P. H., & Bokey, E. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.109 · Cited by 117
Functional Analysis of the Subunits of the Chromatin Assembly Factor RSF
Loyola, A., Huang, J., LeRoy, G., Hu, S., Wang, Y.-H., DONNELLY, R. J., Lane, W. S., Lee, S.-C., & Reinberg, D. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.19.6759-6768.2003 · Cited by 117
Molecular determinants of treatment response in human germ cell tumors.
Mayer, F., Stoop, H., Scheffer, G. L., Scheper, R. J., Oosterhuis, J. W., Looijenga, L. H. J., & Bokemeyer, C. (2003) · PubMed · Cited by 116
Self-citationDuffy, M. J., Duggan, C. R., Keane, R., Hill, A. D. K., McDermott, E. W. M., Crown, J. P., & O’Higgins, N. J. (2004) · Clinical Chemistry · doi:10.1373/clinchem.2003.025288 · Cited by 116
Self-citationZoorob, R., Anderson, R., Cefalu, C. A., & Sidani, M. A. (1991) · PubMed · Cited by 113
Microsatellite instability of germ cell tumors is associated with resistance to systemic treatment.
Mayer, F., Gillis, A., Dinjens, W. N. M., Oosterhuis, J. W., Bokemeyer, C., & Looijenga, L. H. J. (2002) · PubMed · Cited by 111
Self-citationCorrelation between retinoblastoma gene expression and differentiation in human testicular tumors.
Strohmeyer, T. G., Reissmann, P. T., Cordon‐Cardo, C., Hartmann, M., Ackermann, R., & Slamon, D. J. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.15.6662 · Cited by 110
Restricted 12p Amplification and RAS Mutation in Human Germ Cell Tumors of the Adult Testis
Roelofs, H., Mostert, M. C., Pompe, K., Zafarana, G., van Oorschot, M., van Gurp, R. J. H. L. M., Gillis, A., Stoop, H., Beverloo, B. H. B., Oosterhuis, J. W., et al. (2000) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64631-7 · Cited by 110
Self-citationVogelzang, N. J., Lange, P. H., Goldman, A. I., Vessela, R. H., Fraley, E. E., & Kennedy, B. J. (1982) · PubMed · Cited by 109
Osteopontin as an Adjunct to CA125 in Detecting Recurrent Ovarian Cancer
Schorge, J. O., Drake, R. D., Lee, H., Skates, S. J., Rajanbabu, R., Miller, D. S., Kim, J., Cramer, D. W., Berkowitz, R. S., & Mok, S. C. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0365 · Cited by 108
Camilleri‐Broët, S., Bessard, A. C. H., Tourneau, A. L., Paraiso, D., Levrel, O., Leduc, B., Bain, S., Orfeuvre, H., Audouin, J., & Pujade-Lauraine, É. (2003) · Annals of Oncology · doi:10.1093/annonc/mdh021 · Cited by 108
Evaluation of the Abbott IMx® Automated Immunoassay of Prostate-Specific Antigen
Vessella, R. L., Noteboom, J. L., & Lange, P. H. (1992) · Clinical Chemistry · doi:10.1093/clinchem/38.10.2044 · Cited by 107
CA 125 in Ovarian Cancer: Advances and Controversy
Fritsche, H. A., & Bast, R. C. (1998) · Clinical Chemistry · doi:10.1093/clinchem/44.7.1379 · Cited by 106
Self-citationHuman kallikrein 10: a novel tumor marker for ovarian carcinoma?
Luo, L., Bunting, P. S., Scorilas, A., & Diamandis, E. P. (2001) · Clinica Chimica Acta · doi:10.1016/s0009-8981(01)00401-6 · Cited by 106
Self-citationBirken, S., Berger, P., Bidart, J., Weber, M. M., Bristow, A., Norman, R. J., Sturgeon, C. M., & Stenman, U. (2003) · Clinical Chemistry · doi:10.1373/49.1.144 · Cited by 105
Self-citationRiedinger, J., Wafflart, J., Ricolleau, G., Eche, N., Larbre, H., Basuyau, J. P., Dalifard, I., Hacène, K., & Pichon, M.-F. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl120 · Cited by 103
The role of CA 125 in the early diagnosis of progressive disease in ovarian cancer
van der Burg, M. E. L., Lammes, F. B., & Verweij, J. (1990) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a057754 · Cited by 103
The ISOBM TD-7 Workshop on hCG and Related Molecules
Berger, P., Sturgeon, C. M., Bidart, J., Paus, E., Gerth, R., Niang, M. S., Bristow, A., Birken, S., & Stenman, U. (2002) · Tumor Biology · doi:10.1159/000048686 · Cited by 101
Self-citationDiagnosis and treatment of prostate cancer: summary of NICE guidance
Graham, J. D., Baker, M. R., Macbeth, F. R., et al. (2008) · BMJ · doi:10.1136/bmj.39498.525706.ad · Cited by 101
Chambers, S. K., Ivins, C. M., & Carcangiu, M. L. (1998) · International Journal of Cancer · Cited by 99
Aschele, C., Lonardi, S., & Monfardini, S. (2002) · Cancer Treatment Reviews · doi:10.1053/ctrv.2002.0253 · Cited by 99
X inactivation in human testicular tumors. XIST expression and androgen receptor methylation status.
Looijenga, L. H. J., Gillis, A., van Gurp, R. J., Verkerk, A. J. M. H., & Oosterhuis, J. W. (1997) · Europe PMC (PubMed Central) · Cited by 97
Self-citationPerlin, E., Engeler, J. E., Edson, M., Karp, D., McIntire, K. R., & Waldmann, T. A. (1976) · Cancer · doi:10.1002/1097-0142(197601)37:1<215::aid-cncr2820370131>3.0.co;2-l · Cited by 95
Fisher, E. R., Anderson, S., Dean, S., Dabbs, D. J., Fisher, B., Siderits, R. H., Pritchard, J., Pereira, T. C., Geyer, C. E., & Wolmark, N. (2004) · Cancer · doi:10.1002/cncr.20761 · Cited by 93
Chromosomal amplification is associated with cisplatin resistance of human male germ cell tumors.
Rao, P. H., Houldsworth, J., Palanisamy, N., Murty, V. V. V. S., Reuter, V. E., Motzer, R. J., Bosl, G. J., & Chaganti, R. S. K. (1998) · PubMed · Cited by 92
Pestalozzi, B. C., Luporsi, É., Jost, L. M., & Bergh, J. C. S. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi825 · Cited by 92
Stratmann, A., Acker, T., Burger, A. M., Amann, K., Risau, W., & Plate, K. H. (2001) · International Journal of Cancer · doi:10.1002/1097-0215(200002)9999:9999<::aid-ijc1054>3.0.co;2-q · Cited by 91
Nilsson, O., Johansson, C., Glimelius, B. L. G., Persson, B., Nørgaard‐Pedersen, B., Andrén‐Sandberg, Å., & Lindholm, L. (1992) · British Journal of Cancer · doi:10.1038/bjc.1992.44 · Cited by 89
Mayer, F., Honecker, F. U., Looijenga, L. H. J., & Bokemeyer, C. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg242 · Cited by 89
Self-citationInherited Susceptibility to Colorectal Cancer
Rowley, P. T. (2005) · Annual Review of Medicine · doi:10.1146/annurev.med.56.061704.135235 · Cited by 88
Qian, J., Hirasawa, K., Bostwick, D. G., Bergstralh, E. J., Slezak, J. M., Anderl, K. L., Borell, T. J., Lieber, M. M., & Jenkins, R. B. (2002) · Modern Pathology · doi:10.1038/modpathol.3880487 · Cited by 86
Evans, R. M., Edwards, A., Brett, J., Bradburn, M. J., Watson, E. K., Austoker, J., & Elwyn, G. J. (2004) · Patient Education and Counseling · doi:10.1016/j.pec.2004.06.009 · Cited by 86
Johnston, P. G., Benson, A. B., Catalano, P. J., Rao, M. S., O'Dwyer, P. J., & Allegra, C. J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.07.039 · Cited by 82
CA 125: fundamental and clinical aspects
Verheijen, R. H. M., von Mensdorff‐Pouilly, S., van Kamp, G. J., & Kenemans, P. (1999) · Seminars in Cancer Biology · doi:10.1006/scbi.1998.0114 · Cited by 80
Elevated α-Methylacyl-CoA Racemase Enzymatic Activity in Prostate Cancer
Kumar‐Sinha, C., Shah, R. B., Laxman, B., Tomlins, S. A., Harwood, J., Schmitz, W., Conzelmann, E., Sanda, M. G., Wei, J. T., Rubin, M. A., et al. (2004) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63167-7 · Cited by 79
Primary colon cancer: ESMO Clinical Recommendations for diagnosis, adjuvant treatment and follow-up
Cutsem, E. V., & Oliveira, J. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp126 · Cited by 79
Cytokeratins and Tissue Polypeptide Antigen
Sundström, B., & Stigbrand, T. I. (1994) · The International Journal of Biological Markers · doi:10.1177/172460089400900207 · Cited by 77
Mano, M. S., Rosa, D. D., de Azambuja, E., Ismael, G., & Durbecq, V. (2006) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2006.10.001 · Cited by 76
Antibody-Based Profiling of the Phosphoinositide 3-Kinase Pathway in Clinical Prostate Cancer
THOMAS, G. V., Horvath, S., Smith, B. L., Crosby, K., Lebel, L. A., Schrage, M. I., Said, J. W., Kernion, J. D., Reiter, R. E., & Sawyers, C. L. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0130 · Cited by 76
Browne, T.-J., Hirsch, M. S., BRODSKY, G. L., et al. (2004) · Human Pathology · doi:10.1016/j.humpath.2004.09.009 · Cited by 75
James, L. M., Kelsey, A. M., Birch, J. M., & Varley, J. M. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6990691 · Cited by 75
Prognostic role of serum CA15.3 in 362 node-negative breast cancers. An old player for a new game
Gion, M., Boracchi, P., Dittadi, R., Biganzoli, E. M., Peloso, L., Mione, R., Gatti, C., Paccagnella, A., & Marubini, E. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00426-9 · Cited by 73
Spierings, D. C. J., de Vries, E. G. E., Vellenga, E., & de Jong, S. (2003) · The Journal of Pathology · doi:10.1002/path.1373 · Cited by 72
Breast Cancer: Achievements in Adjuvant Systemic Therapies in the Pre-Genomic Era
Colozza, M., de Azambuja, E., Cardoso, F., Bernard, C., & Piccart, M. J. (2006) · The Oncologist · doi:10.1634/theoncologist.11-2-111 · Cited by 72
Marker Half-Life Analysis as a Prognostic Tool in Testicular Cancer
Lange, P. H., Vogelzang, N. J., Goldman, A. I., Kennedy, B. J., & Fraley, E. E. (1982) · The Journal of Urology · doi:10.1016/s0022-5347(17)53149-3 · Cited by 72
Prognostic Value of the Human Kallikrein Gene 15 Expression in Ovarian Cancer
Yousef, G. M., Scorilas, A., Katsaros, D., Fracchioli, S., Iskander, L., Borgoño, C. A., de la Longrais, I. A. R., Puopolo, M., Massobrio, M., & Diamandis, E. P. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.09.111 · Cited by 71
Self-citationBártková, J., Thullberg, M., Meyts, E. R., Skakkebæk, N. E., & Bartek, J. (2000) · International Journal of Cancer · Cited by 71
Raaijmakers, R., BLIJENBERG, B. G., Finlay, J. A., et al. (2004) · The Journal of Urology · doi:10.1097/01.ju.0000127731.56103.50 · Cited by 71
Dual Mechanisms for Lysophosphatidic Acid Stimulation of Human Ovarian Carcinoma Cells
Hu, Y., Albanese, C., Pestell, R. G., & Jaffe, R. B. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.10.733 · Cited by 70
Urokinase-Type Plasminogen Activator System in Breast Cancer
Gelder, M. E. M., Look, M. P., Peters, H. A., Schmitt, M., Brünner, N., Harbeck, N., Klijn, J. G. M., & Foekens, J. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3848 · Cited by 70
Self-citationBenraad, T. J., Geurts-Moespot, J., Grøndahl-Hansen, J., Schmitt, M., Heuvel, J. J. T. M., Witte, J., Foekens, J. A., Leake, R. E., Brünner, N., & Sweep, F. C. G. J. (1996) · European Journal of Cancer · doi:10.1016/0959-8049(96)00118-9 · Cited by 69
Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy
Tuxen, M. K., Sölétormos, G., & Dombernowsky, P. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1787 · Cited by 68
CEA, CA 242, CA 19-9, CA 72-4 and hCGβ in the Diagnosis of Recurrent Colorectal Cancer
Carpelan-Holmström, M. A., Louhimo, J. M., Stenman, U.-H., Alfthan, H. V., rvinen, H. J. J., & Haglund, C. H. (2004) · Tumor Biology · doi:10.1159/000081385 · Cited by 67
Self-citationNicolini, A., Anselmi, L., Michelassi, C., & Carpi, A. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.515 · Cited by 66
Mismatch repair gene expression and genetic instability in testicular germ cell tumor
Velasco, A., Riquelme, E. M., Schultz, M., Wistuba, I. I., Villarroel, L. A., Pizarro, J., Berlín, A., Ittmann, M., Koh, M. S., & Leach, F. S. (2004) · Cancer Biology & Therapy · doi:10.4161/cbt.3.10.1135 · Cited by 62
Deregulation of the G1/S‐phase control in human testicular germ cell tumours
Bártková, J., Meyts, E. R., Skakkebæk, N. E., LUKAS, J., & Bártek, J. (2003) · Apmis · doi:10.1034/j.1600-0463.2003.1110129.x · Cited by 59
Gadducci, A., Cosio, S., FANUCCHI, A., Negri, S., Cristofani, R., & Genazzani, A. R. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2003.12.043 · Cited by 59
Givant-Horwitz, V., Davidson, B., Lazarovici, P., SCHAEFER, E. M., Nesland, J. M., Trope, C. G., & Reich, R. (2003) · Gynecologic Oncology · doi:10.1016/s0090-8258(03)00434-7 · Cited by 58
Tumour markers in prostate cancer: EGTM recommendations
Semjonow, A., Albrecht, W., Bialk, P., Gerl, A., Lamerz, R., Hp, S., & Poppel, H. V. (1999) · Anticancer Research · Cited by 57
Self-citationTuxen, M. K., Sölétormos, G., Petersen, P. H., Schiøler, V., & Dombernowsky, P. (1999) · Gynecologic Oncology · doi:10.1006/gyno.1999.5414 · Cited by 56
Bártková, J., Thullberg, M., Meyts, E. R., Skakkebæk, N. E., & Bartek, J. (2000) · Oncogene · doi:10.1038/sj.onc.1203769 · Cited by 55
Skelly, M. M., Troy, A., Duffy, M. J., Mulcahy, H. E., Duggan, C., Connell, T. G., O’Donoghue, D. P., & Sheahan, K. D. (1997) · PubMed · Cited by 55
Self-citationUpdate on ovarian cancer screening
Munkarah, A. R., Chatterjee, M., & Tainsky, M. A. (2007) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0b013e328011ec99 · Cited by 54
Comparison of seven immunoassays for the quantification of CA 125 antigen in serum
Davelaar, E. M., van Kamp, G. J., Verstraeten, R. A., & Kenemans, P. (1998) · Clinical Chemistry · doi:10.1093/clinchem/44.7.1417 · Cited by 50
hCG, its free subunits and its metabolites. Roles in pregnancy and trophoblastic disease.
Cole, L. A. (1998) · PubMed · Cited by 49
Human kallikrein 11: an indicator of favorable prognosis in ovarian cancer patients
Diamandis, E. P., Borgoño, C. A., Scorilas, A., Harbeck, N., Dorn, J., & Schmitt, M. (2004) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2004.04.009 · Cited by 48
Self-citationCoogan, C. L., Foster, R. S., Rowland, R. G., Bihrle, R., Smith, E. R., Einhorn, L. H., Roth, B. J., & Donohue, J. P. (1997) · Urology · doi:10.1016/s0090-4295(97)00458-5 · Cited by 48
Expression and prognostic significance of immunoregulatory molecules in esophageal cancer
Hosch, S. B., Izbicki, J. R., Pichlmeier, U., Stoecklein, N. H., Niendorf, A., Knoefel, W. T., Broelsch, C. E., & Pantel, K. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19971219)74:6<571::aid-ijc2>3.0.co;2-r · Cited by 46
Clinical Uses of Microsatellite Instability Testing in Colorectal Cancer: An Ongoing Challenge
Boland, C. R. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.4607 · Cited by 46
Expression of Rsf-1, a chromatin-remodeling gene, in ovarian and breast carcinoma
Mao, T., Hsu, C., Yen, M. J., Gilks, C. B., Sheu, J. J., Gabrielson, E. W., VANG, R. S., Cope, L., Kurman, R. J., Wang, T., et al. (2006) · Human Pathology · doi:10.1016/j.humpath.2006.04.008 · Cited by 44
Self-citationESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of rectal cancer
Tveit, K. M. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg297 · Cited by 42
Steyerberg, E. W., Keizer, H. J., Habbema, J. D. F., & for the ReHiT Study Group (1999) · International Journal of Cancer · Cited by 40
Gao, C., Rawal, S. K., Sun, L. L., Ali, A., Connelly, R. R., Bañez, L. L., Sesterhenn, I. A., McLeod, D. G., Moul, J. W., & Srivastava, S. K. (2003) · PubMed · Cited by 39
HBXAP, a Novel PHD-Finger Protein, Possesses Transcription Repression Activity
Shamay, M., Barak, O. G., & Shaul, Y. (2002) · Genomics · doi:10.1006/geno.2002.6717 · Cited by 39
A systematic review of lactate dehydrogenase isoenzyme 1 and germ cell tumors
von Eyben, F. E. (2001) · Clinical Biochemistry · doi:10.1016/s0009-9120(01)00236-3 · Cited by 38
Watine, J., Miédougé, M., & Friedberg, B. (2001) · Diseases of the Colon & Rectum · doi:10.1007/bf02234457 · Cited by 38
(1989) · Reactions Weekly · doi:10.1007/bf03283864 · Cited by 37
Cutsem, E. V., & Kataja, V. V. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi808 · Cited by 36
Quantitative Immunochemical Fecal Occult Blood Tests: Is It Time to Go Back to the Future?
Imperiale, T. F. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-4-200702200-00013 · Cited by 35
Sehouli, J., Akdogan, Z., Heinze, T., Könsgen, D., Stengel, D., Mustea, A., & Lichtenegger, W. (2003) · PubMed · Cited by 35
Davidson, B., Berner, A., Tropé, C. G., Wang, T., & Shih, I. (2007) · Human Pathology · doi:10.1016/j.humpath.2006.12.009 · Cited by 34
Self-citation
Cited by
Practice Parameters for the Management of Rectal Cancer (Revised)
Monson, J. R. T., Weiser, M. R., Buie, W. D., Chang, G. J., Rafferty, J. F., Buie, W. D., Rafferty, J., Guillem, J., Boushey, R., Chang, G., et al. (2013) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0b013e31828cb66c · Cited by 563
MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress
Felder, M., Kapur, A., Gonzalez-Bosquet, J., Horibata, S., Heintz, J., Albrecht, R., Fass, L., Kaur, J., Hu, K., Shojaei, H., et al. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-129 · Cited by 524
Duffy, M. J., Harbeck, N., Nap, M., Molina, R., Nicolini, A., Senkus, E., & Cardoso, F. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.01.017 · Cited by 522
Self-citationEvidence-Based Clinical Use of Nanoscale Extracellular Vesicles in Nanomedicine
Fais, S., O’Driscoll, L., Borras, F. E., Buzas, E., Camussi, G., Cappello, F., Carvalho, J., Cordeiro da Silva, A., Del Portillo, H., El Andaloussi, S., et al. (2016) · ACS Nano · doi:10.1021/acsnano.5b08015 · Cited by 481
Broza, Y. Y., Zhou, X., Yuan, M., Qu, D., Zheng, Y., Vishinkin, R., Khatib, M., Wu, W., & Haick, H. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00437 · Cited by 461
Metadata
- Authors
- Sturgeon, C. M., Duffy, M. J., Stenman, U.-H., Lilja, H., Brünner, N., Chan, D. W., Babaian, R., Bast, R. C., Dowell, B., Esteva, F. J., Haglund, C., Harbeck, N., Hayes, D. F., Holten-Andersen, M., Klee, G. G., Lamerz, R., Looijenga, L. H., Molina, R., Nielsen, H. J., Rittenhouse, H., Semjonow, A., Shih, I.-M., Sibley, P., Sölétormos, G., Stephan, C., Sokoll, L., Hoffman, B. R., & Diamandis, E. P.
- Venue
- Clinical Chemistry
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-12-01
- Volume
- 54
- Issue
- 12
- Pages
- e11-e79
- ISSN
- 0009-9147 (ISSN-L)
- 1530-8561
- OpenAlex
- W2099052946
- Cited by
- 1,129
- References
- 416
- FWCI
- 15.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.